MANGOCEUTICALS, INC.
For the period ended Mar 1, 2024. Filed Mar 1, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Mar 1, 2024 · Filed Mar 1, 2024
Use the contents to explore the available documents and sections.
Contents
Potential Consequences if the Reverse Split Proposal is Not Approved
If the Reverse Stock Split is not approved by our stockholders, our Board will not have the authority to effect the Reverse Stock Split to, among other things, facilitate the continued listing of our common stock on The Nasdaq Capital Market by increasing the per share trading price of our common stock to help ensure a share price high enough to satisfy the $1.00 per share minimum bid price requirement. Any inability of our Board to effect the Reverse Stock Split could expose us to delisting from The Nasdaq Capital Market.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.